

Accepted Manuscript

Title: Rivaroxaban vs Warfarin and Risk of Post-Thrombotic Syndrome among Patients with Venous Thromboembolism

Author: Mette Sogaard, Peter Brønnum Nielsen, Flemming Skjøth, Jette Nordstrøm Kjældgaard, Craig I. Coleman, Torben Bjerregaard Larsen

PII: S0002-9343(18)30118-9
DOI: <https://doi.org/10.1016/j.amjmed.2018.01.041>
Reference: AJM 14529

To appear in: *The American Journal of Medicine*



Please cite this article as: Mette Sogaard, Peter Brønnum Nielsen, Flemming Skjøth, Jette Nordstrøm Kjældgaard, Craig I. Coleman, Torben Bjerregaard Larsen, Rivaroxaban vs Warfarin and Risk of Post-Thrombotic Syndrome among Patients with Venous Thromboembolism, *The American Journal of Medicine* (2018), <https://doi.org/10.1016/j.amjmed.2018.01.041>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Rivaroxaban vs warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism

Mette Søgaaard, PhD^{1,2}, Peter Brønnum Nielsen, PhD^{1,2}, Flemming Skjøth, PhD^{2,3}, Jette Nordstrøm Kjældgaard, BSc^{1,2}, Craig I. Coleman, PharmD⁴, Torben Bjerregaard Larsen, PhD^{1,2}

¹Department of Cardiology, Aalborg University Hospital, Denmark

²Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.

³Unit for Clinical Biostatistics, Aalborg University Hospital, Denmark

⁴School of Pharmacy, University of Connecticut, Storrs, Connecticut, USA

Running title: Post-thrombotic syndrome with rivaroxaban or warfarin

Word count including abstract and text: 2993.

Keywords: Rivaroxaban, warfarin, oral anticoagulation, deep venous thrombosis, post thrombotic syndrome.

Funding: Obel Family Foundation.

Conflict of interest: Torben Larsen has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim, and has been on the speaker bureaus for Bayer, BMS/Pfizer, Roche Diagnostics, Boehringer Ingelheim and Takeda Pharma. Flemming Skjøth has been consultant for Bayer. Peter Brønnum Nielsen has received speaking fees from Boehringer Ingelheim, consulting fees from Bayer; and grant support from BMS/Pfizer. Craig I. Coleman has received grant funding and consulting fees from Bayer AG, Janssen Pharmaceuticals and Boehringer Ingelheim Pharmaceuticals. Other authors – none declared.

Download English Version:

<https://daneshyari.com/en/article/8603760>

Download Persian Version:

<https://daneshyari.com/article/8603760>

[Daneshyari.com](https://daneshyari.com)